Biotechnology

Global Pharma, Biotech & Diagnostics Collaborative R&D Partnering Analysis Report 2023 with a Directory of Over 6,000 Deals Signed Since 2016

by

DUBLIN, May 19, 2023 /PRNewswire/ — The “Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2016-2023” report has been added to  ResearchAndMarkets.com’s offering. The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive understanding and unprecedented access to 6,000+ collaborative R&D deals and agreements … Read more

RZNOMICS Inc. received FDA approval to initiate clinical development of trans-splicing ribozyme-based RNA editing technology in Glioblastoma Multiforme Patients

by

SEONGNAM, South Korea, May 19, 2023 /PRNewswire/ — Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, recently received Phase 1/2a IND approval from the U.S FDA on May 6th for its Glioblastoma Multiforme (GBM) treatment called RZ-001 and thus has achieved an important milestone for the company and … Read more

ExoCoBio obtained a US Patent for Rose Stem Cell-derived Exosome (RSCE™)

by

–  The first plant stem cell-derived exosome patent in the US –  The 5th patent allowance following 3 in Korea and 1 in Japan –  An important milestone for the global plant stem cell-derived exosome industry SEOUL, South Korea, May 19, 2023 /PRNewswire/ — ExoCoBio, one of the top three exosome companies in the world, … Read more

Positive Results from Interim Analysis of ‘GEN-001’ Plus avelumab (Bavencio®) Phase II Trial

by

SEOUL, South Korea, May 19, 2023 /PRNewswire/ — Genome & Company (CEO: Pae, Jisoo), a global leading microbiome therapeutics developer, announced that this phase II trial (NCT05419362) will continue without modifications to move on to the second stage, based on the positive result of the interim analysis. Using a single-strain bacteria in combination with avelumab (Bavencio®) … Read more

EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A

by

STOCKHOLM, May 19, 2023 /PRNewswire/ — Sobi today announced that the European Medicines Agency (EMA) has accepted and validated a marketing authorisation application for efanesoctocog alfa, a new class of high-sustained FVIII developed for the treatment of people with haemophilia A of all age groups. The application is based on data from the pivotal XTEND-1 … Read more

EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A

by

STOCKHOLM, May 19, 2023 /PRNewswire/ — Sobi today announced that the European Medicines Agency (EMA) has accepted and validated a marketing authorisation application for efanesoctocog alfa, a new class of high-sustained FVIII developed for the treatment of people with haemophilia A of all age groups. The application is based on data from the pivotal XTEND-1 … Read more

OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

by

EWING, N.J. and SAN DIEGO, May 18, 2023 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient’s immune system to target cancer cells and eradicate disease, today announced the closing of its previously announced registered direct offering of 1,408,384 shares of its … Read more

HemoShear Attends Piper Sandler Conference

by

CHARLOTTESVILLE, Va., May 18, 2023 /PRNewswire/ — HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, participated in the Piper Sandler Spring Biopharma Symposium being held in Boston, MA, Wednesday, May 17 through Thursday, May 18, 2023. The HemoShear management team, led by Brian Wamhoff, Interim CEO, briefed institutional investors on the latest company … Read more

TPU de grado médico de primera calidad, de primera calidad, facilitados por la fábrica inteligente: ICP DAS

by

HSINCHU, 18 de mayo de 2023 /PRNewswire/ — La fabricación inteligente y el estricto control de procesos mejoran la calidad de los TPU. ICP DAS – BMP (polímeros biomédicos), un proveedor de TPU (poliuretano termoplástico) de grado médico con sede en Taiwan, actúa como líder que implementa sistemas IIoT en una fábrica inteligente para mantener … Read more

HuidaGene Therapeutics Announces Publication of the World’s First Guanine Base-Editor

by

SHANGHAI and CLINTON, N.J., May 18, 2023 /PRNewswire/ — HuidaGene Therapeutics (辉大基因; HuidaGene), a clinical-stage genome-editing company, today announced the online National Science Review published the comprehensive data from a study of the world’s first DNA base editor converting G-to-Y, glycosylase-based guanine base editor (gGBE). Company has filed an international patent application for this base … Read more